Oraianthi Fiste MEDICAL ONCOLOGY Consultant, 2nd Medical Oncology Department, Mitera Hospital

+30 694 181070
+30 210 686 9835
ofiste@hygeia.gr
ofiste@med.uoa.gr

Education & Academic Qualifications

MD, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece (2008 – 2014)
Erasmus Lifelong Learning Program, Medizinische Universität Innsbruck, Innsbruck Austria (03/2013 – 07/2013)
MSc in Lung Cancer, National and Kapodistrian University of Athens, Athens, Greece (2015 – 2017)
MSc in Clinical Trials, National and Kapodistrian University of Athens, Athens, Greece (2018 – 2020)
PhD, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece – Thesis title: Insights into Cardiovascular Toxicity of CDK4/6 Inhibitors in Breast Cancer Patients (2020 – 2024)
Bioethics: The law, medicine, and ethics of reproductive technologies and genetics (e-learning program), HarvardX, Harvard Law School (2024)

Fellowship in Societies, Membership in Journal Editorial Committees

Hellenic Group of Young Oncologists (HeGYO)
Hellenic Society of Medical Oncology (HeSMO)
European Society for Medical Oncology (ESMO)
American Society of Clinical Oncology (ASCO)
European Network of Young Gynae Oncologists (ENYGO)
European Association for Cancer Research (EACR)
In Silico Oncology and In Silico Medicine Group
Editorial board of PubMed-indexed BMC Cancer journal

Work Experience

Medical Oncologist – Clinical Research Fellow, Oncology Unit, 3rd Department of Internal Medicine and Laboratory, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece (02/2023 – 10/2025)
Medical Oncology Fellow, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece (11/2019 – 12/2022)
Resident in Internal Medicine, 401 Military General Hospital, Athens, Athens, Greece (11/2016 – 11/2019)

Clinical & Research Interest

Gynaecological malignancies
Breast cancer
Lung cancer
Sub-investigator in 32 clinical trials of lung and breast cancer, phases Ib – IV

Honors & Awards

Hellenic Society of Medical Oncology (HeSMO) Research Grant of €2,000 to support translational cancer research (2023)
Hellenic Society of Medical Oncology (HeSMO) Research Grant of €2,500 to support translational cancer research (2021)
State Scholarships Foundation of Greece: Erasmus Program (2013)
Eurobank EFG group “Best of the Best” award received from the President of the Hellenic Republic and a grant of €1,000 as a high-school graduate who achieved top marks in the university entrance exams (2009)

Recent Publications

https://scholar.google.com/citations?user=6YNZRHAAAAAJ&hl=en (citations: 447, h-index: 14)
- Fiste O, Liontos M, Labidi-Galy SI. Editorial: PARP inhibitors resistance: new insights in ovarian cancer therapy. Front. Oncol. 15:1680969. doi: 10.3389/fonc.2025.1680969
- Fiste O, Samiotaki M, Manios E, Trika C, Liacos CI, Dimitrakakis C, Dimopoulos MA, Gavriatopoulou M, Zagouri F. Serum Proteomics of Ribociclib-Mediated Cardiovascular Toxicity: An Exploratory Case-Control Study. Proteomics Clin Appl. 2025 Aug 29:e70021. doi: 10.1002/prca.70021
- Fiste O, Vamvakas L, Katsaounis P, et al. Adjuvant taxane-based chemotherapy treatment in older patients with early breast cancer: A pooled analysis of five phase III trials from the Hellenic Oncology Research Group. J Geriatr Oncol. 2025 Jan 8. doi: 10.1016/j.jgo.2024.102184
- Fiste O, Mavrothalassitis E, Kokkalis A, et al. Inflammation-related biomarkers as predictors of pathological complete response in early-stage breast cancer. Clin Transl Oncol. 2024 Dec 12. doi: 10.1007/s12094-024-03814-9
- Fiste O, Mavrothalassitis E, Apostolidou K, et al. Cardiovascular complications of ribociclib in breast cancer patients. Crit Rev Oncol Hematol. 2024 Apr;196:104296. doi: 10.1016/j.critrevonc.2024.104296
- Fiste O, Trika C, Syrigos KN, Kotteas EA. A Rare Case of Takotsubo Cardiomyopathy. Eur Rev Med Pharmacol Sci. 2024 Mar;28(5):2063-2067. doi: 10.26355/eurrev_202403_35619
- Fiste O, Gkiozos I, Charpidou A, Syrigos NK. Artificial Intelligence-Based Treatment Decisions: A New Era for NSCLC. Cancers. 2024; 16(4):831. doi.org/10.3390/cancers16040831
- Fiste O, Liontos M, Gavriatopoulou M, et al. CDK4/6 inhibitors and cardiovascular toxicity: Real-world evidence. J Clin Oncol 41, 2023 (suppl; abstr e15074). doi.org/10.1200/JCO.2023.41.16_suppl.e15074
- Fiste O, Mavrothalassitis E, Markellos C, et al. Subarachnoid hemorrhage in a postpartum mother: A rare manifestation of an uncommon disease. Gynecol Oncol Rep. 2022 Oct 25;44:101092. doi: 10.1016/j.gore.2022.101092
- Fiste O, Liontos M, Zagouri F, et al. Machine learning applications in gynecological cancer: A critical review. Crit Rev Oncol Hematol. 2022 Sep 7;179:103808. doi: 10.1016/j.critrevonc.2022.103808

Print the profile Send via email